Skip to content
PeptideGeek

Weight loss

Lixisenatide, explained simply

A short-acting GLP-1 injection (Adlyxin) taken before the day's main meal to blunt after-meal blood sugar spikes.

Well studied in peopleInjection under the skin (like insulin shots)6 cited sources

Start here

What is Lixisenatide?

Lixisenatide is an FDA-approved once-daily injection for type 2 diabetes 6. It is a short-acting member of the GLP-1 (a gut hormone that tells your brain you're full) class — drugs modeled on a natural gut hormone — and its particular strength is controlling the blood sugar spike after meals, largely by slowing how quickly the stomach empties 23. It is also sold combined with basal insulin as Soliqua 4.

How it works in your body

Lixisenatide copies a gut hormone that manages blood sugar after you eat. It prompts the pancreas to release insulin only when blood sugar is high, and it quiets glucagon, the hormone that tells the liver to release stored sugar. Its standout feature is strongly slowing how fast food leaves your stomach, which blunts the blood sugar spike after a meal and helps you feel full. One injection a day mainly covers the next meal eaten after the shot 6.

The deeper mechanism, for the curious

Lixisenatide is a lab-made GLP-1 receptor agonist (a drug that copies a gut hormone called GLP-1). It is a chain of 44 amino acids, capped at one end (amidated at its C-terminus), with a molecular weight of about 4.86 kDa (a measure of molecular size). 6 It raises insulin release only when blood sugar is high, lowers glucagon (a hormone that raises blood sugar) and slows gastric emptying (how fast the stomach empties). 6 Its mean terminal half-life (the time for half the drug to leave the body) is about 3 hours, and the body clears it by glomerular filtration (kidney filtering) and proteolytic breakdown (being cut up by protein-cutting enzymes). 6 Because it is short-acting, its main effect is on the meal that follows the injection. In a clinical pharmacology study, it lowered blood sugar after meals the most after the first meal of the day, with a weaker effect at later meals. 6 In a head-to-head trial, lixisenatide slowed gastric emptying more than liraglutide. 3

Evidence check

Well studied in people

This has been through large human trials — the strongest kind of evidence. Scientists have tested it on many people and measured what actually happened.

Every numbered marker on this page links to one of the 6 sources at the bottom.

9/100

Blood Sugar Control

Strong reduction in blood sugar after meals through GLP-1 receptor activation, slower stomach emptying, and glucose-dependent insulin release

7/100

Heart Safety

Demonstrated cardiovascular safety in the ELIXA trial with no increased risk of major adverse cardiovascular events

6/100

Weight Management

Modest weight reduction through appetite suppression and delayed gastric emptying, though less pronounced than long-acting GLP-1 RAs

What the research points to

The most-asked question

How much Lixisenatide do I take?

Lixisenatide is dose-escalated: the studies start everyone low and step the dose up on a schedule, so the right amount depends on the week you're on. The research-reported maintenance range is 20 mcg, once daily.

  1. Days 1-14

    10 mcg

    • How often
      Once daily
    • Used for
      Tolerability assessment, GI side-effect mitigation
    • How
      Injection under the skin

    FDA-label (Adlyxin) starting dose given once daily for 14 days using the green starter pen; injected in abdomen, thigh, or upper arm within one hour before the first meal of the day 6.

  2. From day 15 onward

    20 mcg

    • How often
      Once daily
    • Used for
      Type 2 diabetes glycemic control
    • How
      Injection under the skin

    FDA-label maintenance dose, started on day 15 using the burgundy pen for ongoing type 2 diabetes glycemic control (keeping blood sugar steady) 6.

Each step of the schedule, drawn on one scale — 0 to 20 mcg.
  1. Days 1-1410 mcg
  2. From day 15 onward20 mcg

Adjusting your dose

You're at the right dose if…

  • Therapeutic goals being met with minimal side effects
  • Stable and consistent response to treatment
  • Lab values or clinical markers trending in the right direction
  • Good tolerance with manageable or absent side effects

Consider going up if…

  • You've tolerated the current dose for the recommended period without significant side effects
  • Therapeutic goals haven't been met at the current dose level
  • Your healthcare provider recommends dose escalation based on your response
  • Lab work or clinical assessments support a higher dose

Go down if…

  • Side effects are bothersome or impacting daily life despite management strategies
  • You experience any signs of an adverse reaction
  • Lab results indicate the need for dose reduction
  • Your healthcare provider recommends a lower dose based on your response

The ceiling: 20 mcg (as determined by your healthcare provider based on individual response and tolerance)

Reconstitution, in plain words

How do I mix Lixisenatide?

Peptides usually arrive as a freeze-dried powder in a small vial. “Reconstitution” just means adding sterile water back in so you can measure a dose. Here's how it works for Lixisenatide:

What you need

  • Lixisenatide vial (lyophilized powder or solution)
  • Bacteriostatic water or sterile sodium chloride for reconstitution
  • Alcohol swabs for cleaning vial tops and injection sites
  • Appropriately sized syringes with fine-gauge needles (27-30 gauge)
  • Sharps disposal container

A worked example

Add the recommended volume of bacteriostatic water to the Lixisenatide vial. Gently swirl (do not shake) until the powder is fully dissolved. The resulting solution should be clear. Calculate your individual dose based on the concentration and your prescribed amount.

Working out your dose

Your dose of Lixisenatide is determined by your healthcare provider. Using an insulin syringe marked in units, draw up the exact amount prescribed. For example, if the reconstituted concentration is 1mg/mL and your dose is 0.5mg, draw up 0.5mL (50 units on an insulin syringe). Always double-check calculations before injection.

Or let the calculator do it

Three quick questions — your vial, your water, your dose — and it tells you the exact syringe mark. “Find dose amount” is preloaded with Lixisenatide's recorded schedule.

LixisenatideOnce daily

How much peptide is in your bottle?

Look at the label on the vial. It’s the number next to the unit — like "5 mg". Labeled in IU? Switch the unit to IU.

Type a number to continue.
0

Injection sites & technique

Where do I inject Lixisenatide?

The best spots

  • Abdomen (stomach area)—at least 2 inches from the belly button, most popular choice for self-injection
  • Front of thighs—middle to upper portion of the outer leg
  • Back of upper arm—outer area (may need assistance from another person)

How to do it, step by step

  • Wash your hands thoroughly with soap and water before handling supplies
  • Clean the injection site with an alcohol swab and let it air dry completely
  • Pinch a fold of skin at the chosen injection site
  • Insert the needle at a 45-90 degree angle (depending on needle length and body composition)
  • Inject the medication slowly and steadily over 5-10 seconds
  • Release the skin fold and remove the needle, applying gentle pressure with a clean swab
  • Rotate injection sites to prevent tissue irritation or lipodystrophy (lumps or dents in fatty tissue)
  • Dispose of the needle safely in a sharps container—never recap or reuse needles

Subcutaneous (under the skin) injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training

Timing

When do I take Lixisenatide?

Best time of day

Inject once daily within one hour before the first meal of the day, preferably before the same meal each day. 6 If a dose is missed, inject it within one hour before the next meal. 6

With or without food?

Timing to a meal matters: lixisenatide's glucose-lowering effect is strongest on the meal after the injection and weaker at later meals. 6 Take time-sensitive oral medications (antibiotics, acetaminophen) at least 1 hour before the injection. 6

Taking it with other peptides

Lixisenatide should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.

The honest list

What side effects could Lixisenatide cause?

Common — usually mild

These show up most often. They usually fade as your body adjusts.

  • Nausea

    Most frequently reported side effect, affecting 25-28% of patients in clinical trials. Typically mild to moderate and most pronounced during the initial dose-titration (stepping the dose up gradually) period.

    What to do Start at 10 mcg for 14 days before increasing to 20 mcg. Take before meals as directed. Symptoms typically diminish within the first 2-4 weeks of treatment.

  • Vomiting

    Occurs in approximately 10% of patients, usually together with nausea early in treatment. Caused by the drug's GLP-1 (a gut hormone that tells your brain you're full) action slowing stomach emptying.

    What to do Eat smaller meals, avoid high-fat foods during initiation. Ensure adequate hydration. If persistent, consult prescriber about temporary dose reduction.

  • Diarrhea

    Reported in 7-8% of patients. Usually temporary, and caused by the drug's GLP-1 (a gut hormone that tells your brain you're full) action changing gut movement.

    What to do Maintain hydration and balanced diet. Symptoms typically resolve without intervention. If severe or persistent, contact healthcare provider.

  • Headache

    Mild headaches reported in approximately 9% of patients. May be related to metabolic changes during early treatment with GLP-1 receptor agonists (drugs that mimic the gut's fullness hormone).

    What to do Usually resolves with continued use. Standard analgesics may be used for relief. Ensure adequate hydration and consistent meal timing.

Less common

Worth knowing about, but most people never see these.

  • Injection Site Reactions

    Local reactions at the injection site including redness, itching, or mild swelling reported in approximately 3-4% of patients.

    What to do Rotate injection sites between abdomen, thigh, and upper arm. Allow injected solution to reach room temperature before use. Clean site properly before injection.

Serious — stop and get medical help

Rare, but if any of these happen, stop and contact a medical professional.

  • Sudden inflammation of the pancreas (acute pancreatitis)

    Rare cases of acute pancreatitis have been reported with GLP-1 receptor agonists (drugs that mimic the gut's fullness hormone). Patients should be monitored for signs including severe persistent abdominal pain.

    What to do Discontinue lixisenatide immediately if pancreatitis is suspected. Seek emergency medical attention for severe, persistent abdominal pain radiating to the back. Do not restart if pancreatitis is confirmed.

Week by week

What should I expect from Lixisenatide, and when?

  1. Weeks 1-2

    You might notice
    • Blood sugar after meals starts to improve. Nausea is possible as your body adjusts to the drug during the 10 mcg starting-dose period
    What's normal
    • Nausea, mild appetite reduction, and slight changes in bowel habits are common during this initiation phase
    • Some patients notice reduced hunger after meals within days
    What's next
    • After 14 days at 10 mcg, the dose goes up to the full 20 mcg maintenance dose, and blood sugar is expected to improve further

  2. Weeks 3-8

    You might notice
    • More consistent postprandial glucose control at the full 20 mcg dose, GI side effects typically diminishing, early weight stabilization or modest loss
    What's normal
    • Nausea should begin to subside significantly
    • Postprandial glucose readings will show improvement
    • Fasting glucose may improve modestly
    • Weight may begin a gradual downward trend
    What's next
    • Continue treatment at 20 mcg daily
    • HbA1c (a blood test showing your average blood sugar over about 3 months) at 12-16 weeks will show the total blood-sugar benefit

  3. Weeks 12-24

    You might notice
    What's normal
    • Stomach and gut side effects should be mild or gone
    • Blood sugar control should be steady
    • Any weight loss tends to level off at modest amounts, compared with long-acting GLP-1 (a gut hormone that tells your brain you're full) drugs
    What's next
    • Check your overall response with HbA1c (a blood test of average blood sugar)
    • If targets are not met, consider adding basal insulin (long-acting background insulin) or switching to a fixed-ratio combination (Soliqua)

How to tell it's actually working

Treatment Response

  • Improvement in the primary symptoms or condition being treated
  • Positive changes in relevant lab values or clinical markers
  • Consistent, stable response to Lixisenatide over time
  • Reduction in symptom frequency or severity

General Well-being

  • Improved energy levels and daily functioning
  • Better quality of life related to the treated condition
  • Manageable or absent side effects indicating good tolerance
  • Positive feedback from healthcare provider during check-ups

Not seeing anything? The usual reasons

  • Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
  • Insufficient time at target dose—most compounds need several weeks to show full benefits
  • Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
  • Individual variation in response—genetics, metabolism, and other factors affect outcomes
  • Underlying conditions or medications interfering with absorption or effectiveness
  • Improper storage leading to degraded product—always verify proper storage conditions

Is it right for you?

Who should avoid Lixisenatide?

Do not use it if…

Be extra careful if…

  • You are taking other medications—discuss potential interactions with your healthcare provider
  • You have a history of liver or kidney disease
  • You are elderly or have multiple medical conditions
  • You are planning surgery in the near future—inform your surgeon about Lixisenatide use
  • You have any chronic health conditions that require regular monitoring

When to stop

  • Severe or worsening side effects that don't improve with dose adjustment or supportive care
  • Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
  • Your healthcare provider recommends discontinuation based on your clinical response
  • Development of any new medical condition that may be contraindicated with Lixisenatide
  • Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
  • Abnormal lab results or clinical markers that suggest adverse effects

Lixisenatide should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.

What it mixes badly (and well) with

Medications

  • Avoid
    Other GLP-1 Receptor Agonists

    Does the same job in the body, so you get more stomach and gut side effects and no added benefit

  • Avoid
    DPP-4 Inhibitors

    Acts on the same gut-hormone (incretin) pathway, so it adds little extra blood sugar lowering

  • Avoid
    Time-sensitive oral medications

    Lixisenatide slows stomach emptying. Take antibiotics and acetaminophen at least 1 hour before the injection, and birth control pills at least 1 hour before or 11 hours after it 6

Other peptides

  • OK together
    Insulin Glargine

    FDA-approved fixed-dose combination (Soliqua 100/33) that covers both fasting blood sugar and blood sugar after meals

  • OK together
    Metformin

    First-choice combination: the two work in different ways, helping control blood sugar and helping the body respond better to insulin

  • OK together
    SGLT2 Inhibitors

    Lowers blood sugar in a different way, by making the kidneys pass sugar out in urine without needing insulin, and adds heart and kidney benefits

Supplements

  • OK together
    Multivitamins

    Generally safe to take alongside Lixisenatide. Space doses apart if taking oral formulations to ensure optimal absorption.

  • OK together
    Electrolyte supplements

    Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.

Who it tends to suit

Managing high blood sugar after meals (postprandial hyperglycemia) in type 2 diabetes

Lixisenatide is particularly well-suited for people focused on managing high blood sugar after meals (postprandial hyperglycemia (high blood sugar)) in type 2 diabetes. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Improving blood sugar control as an add-on to diabetes pills

Lixisenatide is particularly well-suited for individuals focused on improving glycemic control (keeping blood sugar steady) as add-on to oral antidiabetics. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Supporting weight management in people with type 2 diabetes

Lixisenatide is particularly well-suited for individuals focused on supporting weight management in t2dm patients. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Combination treatment with basal insulin glargine (long-acting background insulin)

Lixisenatide is particularly well-suited for individuals focused on combination therapy with basal insulin glargine. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

The safety picture overall

Lixisenatide (ADLYXIN in the US, Lyxumia in the EU) is an FDA-approved GLP-1 receptor agonist (a drug that mimics the gut's fullness hormone) for type 2 diabetes. Its safety record comes from the GetGoal phase 3 trials and the ELIXA heart-outcomes trial. 16 In the pooled placebo-controlled trials, stomach and gut reactions affected 39.7% of patients against 18.4% on placebo, mostly in the first 3 weeks; nausea affected 25% and vomiting 10%. 6 Label warnings cover anaphylaxis (severe allergic reaction) and serious hypersensitivity, pancreatitis (21 cases on lixisenatide against 14 on comparators), low blood sugar when combined with a sulfonylurea (a diabetes pill) or basal insulin, acute kidney injury after severe fluid loss from gut illness, antibody formation, and gallbladder disease. 6 Unlike the long-acting GLP-1 (a gut hormone that tells your brain you're full) drugs, its label carries no boxed warning for thyroid C-cell tumors. 6

Across the GetGoal trials, lixisenatide 20 mcg once daily lowered HbA1c (average blood sugar over about 3 months) by 0.46–0.99% and 2-hour post-meal glucose by 56–143 mg/dL, with weight change from −2.96 to +0.3 kg; severe low blood sugar occurred in under 1.5%. 1 In ELIXA, 6,068 patients with type 2 diabetes and a recent acute coronary syndrome (heart attack or unstable angina) were followed for a median of about 26 months. Major cardiovascular events occurred in 13.4% on lixisenatide against 13.2% on placebo (hazard ratio 1.02, 95% CI 0.89–1.17), meeting the non-inferiority goal (showing it was not worse). 6 In the trials, 70% of patients developed antibodies against lixisenatide by week 24, and the 2.4% with the highest levels had a weaker glucose response. 6

Keeping it good

How do I store Lixisenatide?

Before mixing (powder)

Before first use, store ADLYXIN pens in the refrigerator at 36–46°F (2–8°C). 6 Do not freeze. 6 Keep the pen in its original package to protect it from light. 6 Check the expiration date before use.

After mixing (liquid)

Not applicable — ADLYXIN is a ready-to-use prefilled pen; nothing is mixed. After first use, store it at up to 86°F (30°C) and replace the cap after each use to protect it from light. 6 Discard the pen 14 days after first use. 6 Do not use the solution if it is not clear and colorless or contains particles. 6

Signs it has gone bad

Not our opinion — the published record

What the studies actually found about Lixisenatide

2017

Lixisenatide, a Once-Daily Prandial Glucagon-Like Peptide-1 Receptor Agonist for the Treatment of Adults with Type 2 Diabetes

Systematic review (a structured review of many studies) of the GetGoal programme: lixisenatide 20 µg once daily lowered HbA1c (a blood test of average blood sugar over about 3 months) by 0.46–0.99% and 2-hour postprandial glucose (blood sugar 2 hours after a meal) by 55.86–143.43 mg/dL, with weight change of −2.96 to +0.3 kg. Severe hypoglycaemia (dangerously low blood sugar) was very rare (under 1.5%) and there was no increased risk of cardiovascular events. The most common adverse events were short-lived, mild-to-moderate nausea and vomiting.

Trujillo JM, Goldman J

2020

Effects of sequential treatment with lixisenatide, insulin glargine, or their combination on meal-related glycaemic excursions, insulin and glucagon secretion, and gastric emptying in patients with type 2 diabetes

In 28 adults with type 2 diabetes treated with metformin, lixisenatide mainly lowered blood sugar after meals and insulin glargine (a long-acting insulin) mainly lowered fasting blood sugar. After breakfast, lixisenatide slowed gastric emptying (stomach emptying) and reduced insulin release and glucagon (a hormone that raises blood sugar). Combining it with glargine improved blood sugar lowering because they work in complementary ways.

Meier JJ, Menge BA, Schenker N, et al.

2015

Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial

142 adults treated with insulin glargine (a long-acting insulin) were randomly assigned to lixisenatide 20 µg or liraglutide 1.2 or 1.8 mg for 8 weeks. Lixisenatide lowered post-breakfast blood sugar more and delayed gastric emptying (stomach emptying) more than either liraglutide dose. Liraglutide raised 24-hour heart rate by 9 bpm (beats per minute) against 3 bpm with lixisenatide. Symptomatic hypoglycaemia (low blood sugar with symptoms) was more frequent with lixisenatide, and gastrointestinal (stomach and gut) adverse events were more frequent with liraglutide.

Meier JJ, Rosenstock J, Hincelin-Méry A, et al.

2021

iGlarLixi reduces residual hyperglycemia in Japanese patients with type 2 diabetes uncontrolled on basal insulin: A post-hoc analysis of the LixiLan JP-L trial

Post-hoc analysis (a look back at trial data) of LixiLan JP-L in Japanese adults whose blood sugar was not controlled on basal insulin (long-acting background insulin): with iGlarLixi (insulin glargine plus lixisenatide, 1 unit:1 µg), the share with residual hyperglycaemia (leftover high blood sugar) fell from 32.5% to 15.7% at 26 weeks, while it rose to 36.9% on glargine alone. HbA1c (average blood sugar test) fell 0.72 percentage points more with iGlarLixi.

Yabe D, Iizuka K, Baxter M, et al.

If this isn't the right fit

What people use instead of Lixisenatide

Alternative approaches for weight management support

  • Consult your healthcare provider for alternatives to Lixisenatide based on your specific needs and medical history

Alternative weight management approaches

  • Semaglutide (Wegovy/Ozempic)
  • Liraglutide (Saxenda)
  • AOD-9604

Non-injectable weight management

  • Oral semaglutide (Rybelsus)
  • Phentermine-topiramate (Qsymia)
  • Lifestyle modifications

Your questions

Lixisenatide FAQ

How does lixisenatide differ from long-acting GLP-1 drugs (drugs that copy a gut hormone) like semaglutide or liraglutide?

Lixisenatide is a short-acting GLP-1 receptor agonist (a drug that mimics the gut's fullness hormone) with a half-life (how long it stays active in your body) of about 3 hours, while long-acting drugs like semaglutide have half-lives of days to a week. So lixisenatide mainly targets blood sugar after meals (postprandial glucose) by strongly slowing stomach emptying, whereas long-acting drugs give steadier GLP-1 (a gut hormone that tells your brain you're full) activation that affects both fasting and after-meal glucose. Long-acting drugs generally lower HbA1c (average blood sugar over about 3 months) and weight more, but lixisenatide is especially good at controlling post-meal glucose spikes.

What is Soliqua and how does it relate to lixisenatide?

Soliqua 100/33 is an FDA-approved fixed-ratio combination of insulin glargine (a long-acting background insulin) and lixisenatide in a single injection pen. Each unit delivers 1 unit of insulin glargine and 1/3 mcg of lixisenatide. The two work in complementary ways: background insulin controls fasting glucose while lixisenatide targets glucose after meals. Together they give full blood sugar control with less weight gain and fewer low-blood-sugar episodes than insulin alone.

What did the ELIXA trial show about heart safety?

The ELIXA (Evaluation of Lixisenatide in Acute Coronary Syndrome) trial enrolled 6,068 patients with type 2 diabetes who had a recent acute coronary syndrome event. Over a median follow-up of 25 months, lixisenatide demonstrated cardiovascular safety with a hazard ratio of 1.02 (95% CI: 0.89-1.17) for MACE (major adverse cardiovascular events), meeting its primary noninferiority endpoint. While it did not show cardiovascular superiority, it confirmed that lixisenatide does not increase cardiovascular risk.

When should I take lixisenatide in relation to meals?

Inject lixisenatide subcutaneously (under the skin) in the abdomen, thigh or upper arm within one hour before the first meal of the day, preferably before the same meal each day. 6 If you miss a dose, inject it within one hour before your next meal. 6 Timing matters because its glucose-lowering effect is strongest on the meal that follows the injection. 6

Can lixisenatide be used in type 1 diabetes?

No, lixisenatide is not approved or recommended for type 1 diabetes. It is specifically indicated for type 2 diabetes mellitus, as an add-on to diet and exercise. Type 1 diabetes involves autoimmune destruction of beta cells (the insulin-making cells), and GLP-1 receptor agonists (drugs that mimic the gut's fullness hormone) work mainly by boosting glucose-dependent insulin release from working beta cells.

Does lixisenatide affect the absorption of other oral medications?

Yes. Lixisenatide delays gastric emptying, which can slow the absorption of oral medications. 6 Take antibiotics, acetaminophen and other drugs that need to reach a threshold level quickly at least 1 hour before the injection. 6 Take oral contraceptives at least 1 hour before or at least 11 hours after it: taken 1–4 hours after a dose, their peak levels fell by up to half in the label's study. 6 Drugs with a narrow therapeutic range should be monitored when lixisenatide is started. 6

6 sources

References

Every numbered marker on this page points to one of these. Same sources, same numbering as the Lixisenatide research profile on Peptide Initiative.

  1. Lixisenatide, a Once-Daily Prandial Glucagon-Like Peptide-1 Receptor Agonist for the Treatment of Adults with Type 2 DiabetesTrujillo JM, Goldman J · 2017
  2. Effects of sequential treatment with lixisenatide, insulin glargine, or their combination on meal-related glycaemic excursions, insulin and glucagon secretion, and gastric emptying in patients with type 2 diabetesMeier JJ, Menge BA, Schenker N, et al. · 2020
  3. Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label TrialMeier JJ, Rosenstock J, Hincelin-Méry A, et al. · 2015
  4. iGlarLixi reduces residual hyperglycemia in Japanese patients with type 2 diabetes uncontrolled on basal insulin: A post-hoc analysis of the LixiLan JP-L trialYabe D, Iizuka K, Baxter M, et al. · 2021
  5. Protein Biomarkers and Cardiovascular Outcomes in People With Type 2 Diabetes and Acute Coronary Syndrome: The ELIXA Biomarker StudyGerstein HC, Hess S, Claggett B, et al. · 2022
  6. ADLYXIN (lixisenatide) injection — FDA Prescribing InformationSanofi-Aventis · 2023

Want the deep science?

Read the full Lixisenatide research profile

Every claim on this page traces back to the research database behind Peptide Initiative — studies, citations, clinical trial data, and the technical detail we deliberately left out here.

Open the research profile

More weight loss guides

This guide is education, not medical advice. Talk to a clinician before taking anything.